Australia markets open in 1 hour 16 minutes

Teva Pharmaceutical Industries Limited (TEVA)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
10.75-0.08 (-0.74%)
At close: 4:00PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 511.93B
Enterprise value 337.18B
Trailing P/E N/A
Forward P/E 13.94
PEG ratio (5-yr expected) 10.78
Price/sales (ttm)0.72
Price/book (mrq)1.18
Enterprise value/revenue 32.23
Enterprise value/EBITDA 78.06

Trading information

Stock price history

Beta (5Y monthly) 1.51
52-week change 34.17%
S&P500 52-week change 348.25%
52-week high 313.30
52-week low 38.44
50-day moving average 311.14
200-day moving average 310.54

Share statistics

Avg vol (3-month) 38.96M
Avg vol (10-day) 35.64M
Shares outstanding 51.1B
Implied shares outstanding 6N/A
Float 1.09B
% held by insiders 10.79%
% held by institutions 152.41%
Shares short (30 Mar 2021) 425.04M
Short ratio (30 Mar 2021) 42.79
Short % of float (30 Mar 2021) 4N/A
Short % of shares outstanding (30 Mar 2021) 42.28%
Shares short (prior month 25 Feb 2021) 432.14M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 311 Dec 2017
Ex-dividend date 426 Nov 2017
Last split factor 22:1
Last split date 330 Jun 2004

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)30 Dec 2020


Profit margin -23.95%
Operating margin (ttm)18.34%

Management effectiveness

Return on assets (ttm)3.53%
Return on equity (ttm)-31.38%

Income statement

Revenue (ttm)16.66B
Revenue per share (ttm)15.21
Quarterly revenue growth (yoy)-0.30%
Gross profit (ttm)7.73B
Net income avi to common (ttm)-3.99B
Diluted EPS (ttm)-3.64
Quarterly earnings growth (yoy)37.60%

Balance sheet

Total cash (mrq)2.18B
Total cash per share (mrq)1.99
Total debt (mrq)26.54B
Total debt/equity (mrq)239.90
Current ratio (mrq)0.99
Book value per share (mrq)9.14

Cash flow statement

Operating cash flow (ttm)1.22B
Levered free cash flow (ttm)1.73B